Clinical applications of PD-L1 bioassays for cancer immunotherapy

Programmed death ligand 1 (PD-L1) has emerged as a biomarker that can help to predict responses to immunotherapies targeted against PD-L1 and its receptor (PD-1). Companion tests for evaluating PD-L1 expression as a biomarker of response have been developed for many cancer immunotherapy agents. Thes...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Delong, Wang, Shuhang, Bindeman, Wendy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436438/
https://www.ncbi.nlm.nih.gov/pubmed/28514966
http://dx.doi.org/10.1186/s13045-017-0479-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436438/
https://www.ncbi.nlm.nih.gov/pubmed/28514966
http://dx.doi.org/10.1186/s13045-017-0479-y

Ejemplares similares